ArticleInternational neurourology journal2025
Treatment Outcomes of Patients With Hunner Interstitial Cystitis Who Received Augmentation Enterocystoplasty or Bladder-Preserving Therapy.
Article in International neurourology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner interstitial cystitis (HIC).
methodsFrom 2013 to 2024, patients with cystoscopically confirmed HIC who received AE or non-AE bladder-preserving therapy were retrospectively analyzed. Treatment outcomes were analyzed using the subjective global assessment response, symptoms, and urodynamic parameters. The patients' symptoms and urodynamic parameters were compared between AE and non-AE groups from baseline to follow-up endpoint.
resultsA total of 54 patients (48 women and 6 men) were included with a mean age of 58.6±11.4 years at diagnosis and a mean follow-up period of 9.4±5.8 years. AE and non-AE therapy was performed in 17 (31.5%) and 37 patients (68.5%), respectively. A final satisfactory outcome was reported in 13 (76.5%) of the 17 HIC patients after AE and in 26 of the 37 patients (70.3%) after non-AE therapy. Compared with patients who had no improvement, patients who had improved outcomes after AE exhibited decreased interstitial cystitis symptom index (P=0.007) and visual analogue scale (P=0.013) scores and increased bladder fullness sensation (P=0.002) and cystometric bladder capacity (P=0.019). Patients who had no improved outcomes after AE did not experience pain relief or increased bladder fullness sensation or bladder capacity. Only 23.4% of the patients treated with AE required repeat surgery or intravesical therapy in the first 1-3 years. By contrast, patients treated with non-AE therapy required repeat intravesical therapy for the recurrence of Hunner lesions or bladder symptoms.
conclusionBoth AE or non-AE therapy can result in satisfactory outcomes in more than 70% of HIC patients. AE provides early relief of bladder pain and increases bladder capacity, and non-AE therapy can also relieve pain and improve functional bladder capacity, resulting in improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.